JP2002507967A - 疾病治療のための抗cd40lイムノトキシン - Google Patents
疾病治療のための抗cd40lイムノトキシンInfo
- Publication number
- JP2002507967A JP2002507967A JP50421299A JP50421299A JP2002507967A JP 2002507967 A JP2002507967 A JP 2002507967A JP 50421299 A JP50421299 A JP 50421299A JP 50421299 A JP50421299 A JP 50421299A JP 2002507967 A JP2002507967 A JP 2002507967A
- Authority
- JP
- Japan
- Prior art keywords
- immunotoxin
- molecule
- cd40l
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.イムノトキシン分子であって、 毒素分子あるいはその活性フラグメントに結合された、ヒト細胞表面上のヒト CD40L抗原に対して特異的な抗体を有し、 前記イムノトキシンのCD40L分子への結合により、CD40L発現細胞を死滅 させる、イムノトキシン分子。 2.前記抗体は、モノクローナル抗体、人体に適合化された抗体、あるいは単鎖 抗体であって、前記モノクローナル抗体の特異性がほぼ保持されている、請求項 1記載のイムノトキシン分子。 3.前記抗体は、抗CD40Lモノクローナル抗体、人体に適合化された抗体、単 鎖抗体、あるいはこれらのフラグメントであって、前記モノクローナル抗体の特 異性がほぼ保持されている、請求項1又は2記載のイムノトキシン分子。 4.前記毒素分子は、リボソーム不活性化タンパク質、又はこの活性フラグメン トである、請求項1〜3のいずれかに記載のイムノトキシン分子。 5.前記毒素分子は、1型リボソーム不活性化タンパク質、又はこの活性フラグ メントである、請求項4記載のイムノトキシン分子。 6.前記毒素分子は、ボウガニンであり、 このボウガニンは、 還元状態あるいは非還元状態下におけるポリアクリルアミドゲル電気泳動によ る分子量が約26000ダルトンであり、 配列番号1によって特定されるアミノ酸配列と少なくとも50%以上の相同性 を有するアミノ末端アミノ酸残基配列を有し、 Bougainvillea spectabilis Willdから分離可能である、 請求項5記載のイムノトキシン分子。 7.前記抗体及び前記毒素分子は、単一の組換えDNA分子によってコードされ 、適切な組換えイムノトキシン分子の宿主細胞系列において発現可能である、請 求項1〜6のいずれかに記載のイムノトキシン分子。 8.前記抗体は、抗CD40Lモノクローナル抗体由来であり、前記毒素は、1型 リボソーム不活性化タンパク質又はその活性フラグメントである、請求項7記載 のイムノトキシン分子。 9.請求項1〜8のいずれかに記載のイムノトキシンの組換え体をコードする核 酸配列と、適切な宿主細胞中で前記イムノトキシンの組換え体を発現可能とする のに必要な制御エレメントを有する、組換え体ベクター。 10.請求項1〜6のいずれかのイムノトキシンを製造する方法であって、 抗CD40Lモノクローナル抗体又はそのフラグメントを毒素分子あるいはその フラグメントに結合させる工程と、 次いで結果物であるイムノトキシンを非結合体から分離する工程、 とを備える、方法。 11.さらに、請求項9に記載のベクターで形質転換された宿主細胞を、前記イ ムノトキシンを前記宿主細胞内で発現可能な条件下で培養する工程と、 培養物から前記イムノトキシンを精製する工程、 とを備える、請求項7又は8に記載の方法。 12.請求項1〜8のいずれかに記載のイムノトキシンを、製剤学的に適合する 賦型剤中に有する、組成物。 13.薬剤用途である、請求項1〜6のいずれかに記載のイムノトキシン分子あ るいは、このイムノトキシンを含む組成物。 14.多発性硬化症、慢性関節リュウマチ、全身性エリテマトーデス、あるいは T細胞悪性腫瘍等の自己免疫疾患の治療方法において用途を有する、請求項1〜 8のいずれかに記載のイムノトキシン分子あるいはこれを含む組成物。 15.多発性硬化症、慢性関節リュウマチ、全身性エリテマトーデス、あるいは T細胞悪性腫瘍等の自己免疫疾患治療方法における薬剤としての、請求項1〜8 のいずれかに記載のイムノトキシン分子あるいはこれを含む組成物の使用。 16.多発性硬化症、慢性関節リュウマチ、及び全身性エリテマトーデス等の 自己免疫疾患の予防及び治療方法における使用のための、請求項1〜8のいずれ かに記載のイムノトキシン分子あるいはこれを含む組成物の使用であって、前記 方法は、治療を要する患者に対して、製剤学的に適合する賦型剤とともに、イム ノトキシン分子あるいは組成物の治療上の有効量を投与する工程を含み、CD40 L抗原への前記イムノトキシンの結合により、自己抗原反応性T細胞の活性化及 び分化を抑制する、イムノトキシン分子あるいは組成物。 17.T細胞悪性腫瘍の治療のための方法における使用のための、請求項1〜8 のいずれかに記載のイムノトキシン分子あるいはその組成物であって、前記方法 は、治療を要する患者に対して、製剤学的に適合する賦型剤とともに、イムノト キシン分子あるいは組成物の治療上の有効量を投与する工程を含み、DC40L抗 原への前記イムノトキシンの結合により、CD40L発現腫瘍細胞を死滅させる、 イムノトキシン分子あるいはその組成物。 18.請求項14に記載の免疫疾患を予防あるいは治療する方法であって、予防 あるいは治療を要する患者に対して、請求項1〜6及び10〜14のいずれかに 記載のイムノトキシンの予防上あるいは治療上の有効量を投与する工程を含み、 CD40L抗原への前記イムノトキシンの結合により、自己抗原反応性T細胞の活 性化及び分化を抑制する、方法。 19.T細胞悪性腫瘍を治療する方法であって、治療を要する患者に対して、請 求項1〜8のいずれかに記載のイムノトキシンの治療上の有効量を投与する工程 を含み、CD40L抗原への前記イムノトキシンの結合により、CD40L発現腫瘍 細胞を死滅させる、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201895.6 | 1997-06-20 | ||
EP97201895 | 1997-06-20 | ||
PCT/NL1998/000357 WO1998058678A1 (en) | 1997-06-20 | 1998-06-22 | Anti-cd40l immunotoxins for the treatment of diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002507967A true JP2002507967A (ja) | 2002-03-12 |
JP2002507967A5 JP2002507967A5 (ja) | 2005-12-22 |
Family
ID=8228468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50421299A Pending JP2002507967A (ja) | 1997-06-20 | 1998-06-22 | 疾病治療のための抗cd40lイムノトキシン |
Country Status (8)
Country | Link |
---|---|
US (1) | US6645494B1 (ja) |
EP (1) | EP1005372B1 (ja) |
JP (1) | JP2002507967A (ja) |
AT (1) | ATE211394T1 (ja) |
AU (1) | AU8132998A (ja) |
CA (1) | CA2294223C (ja) |
DE (1) | DE69803392D1 (ja) |
WO (1) | WO1998058678A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
WO2002087424A2 (en) | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
CA2524441C (en) * | 2003-05-06 | 2012-03-20 | Purdue Research Foundation | Treatment of lupus targeting the macrophages or the folate receptor |
NZ550339A (en) * | 2004-03-19 | 2009-11-27 | Merck Patent Gmbh | Modified bouganin proteins, cytotoxins and methods and uses thereof |
WO2005103086A1 (en) * | 2004-04-23 | 2005-11-03 | Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
AU2008213702B2 (en) | 2007-02-07 | 2014-04-24 | Purdue Research Foundation | Positron emission tomography imaging method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
CA2162689C (en) * | 1993-05-12 | 2000-07-18 | Marc D. Better | Immunotoxins comprising gelonin and an antibody |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
1998
- 1998-06-22 JP JP50421299A patent/JP2002507967A/ja active Pending
- 1998-06-22 EP EP98931129A patent/EP1005372B1/en not_active Expired - Lifetime
- 1998-06-22 CA CA2294223A patent/CA2294223C/en not_active Expired - Fee Related
- 1998-06-22 AU AU81329/98A patent/AU8132998A/en not_active Abandoned
- 1998-06-22 DE DE69803392T patent/DE69803392D1/de not_active Expired - Lifetime
- 1998-06-22 WO PCT/NL1998/000357 patent/WO1998058678A1/en active IP Right Grant
- 1998-06-22 US US09/446,351 patent/US6645494B1/en not_active Expired - Fee Related
- 1998-06-22 AT AT98931129T patent/ATE211394T1/de active
Also Published As
Publication number | Publication date |
---|---|
ATE211394T1 (de) | 2002-01-15 |
EP1005372B1 (en) | 2002-01-02 |
CA2294223A1 (en) | 1998-12-30 |
AU8132998A (en) | 1999-01-04 |
US6645494B1 (en) | 2003-11-11 |
DE69803392D1 (de) | 2002-02-28 |
CA2294223C (en) | 2011-02-15 |
WO1998058678A1 (en) | 1998-12-30 |
EP1005372A1 (en) | 2000-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Seon et al. | Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | |
JP2021168661A (ja) | 三重特異性結合タンパク質と使用方法 | |
RU2228202C2 (ru) | Cd19xcd3-специфические полипептиды и их применение | |
CA2194369C (en) | Methods and compositions for the specific coagulation of vasculature | |
JPH07509444A (ja) | トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法 | |
JPH09503511A (ja) | 細胞および血清タンパク質アンカー並びに接合体 | |
HU208161B (en) | Process for producing cytotoxic active ingredient - antibody conjugates and pharmaceutical compositions | |
Sedlacek et al. | Antibodies as carriers of cytotoxicity | |
JP2002514201A (ja) | 凝固および腫瘍の処置のための組織因子の方法および組成物 | |
JPH09512705A (ja) | E−セレクチンに対する抗体 | |
NZ578635A (en) | Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis | |
US20110142756A1 (en) | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | |
JP2002507967A (ja) | 疾病治療のための抗cd40lイムノトキシン | |
CZ20013270A3 (cs) | Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob | |
JPH10501813A (ja) | 腫瘍処置のための組成物および方法 | |
US6071519A (en) | Immunotoxins specific for CD86 expressing cells | |
JP3892902B2 (ja) | グラム陽性細菌及びマイコバクテリアの作用を阻止するための抗体の使用 | |
JPH08501059A (ja) | Cd33関連表面抗原に対する免疫毒素 | |
EP1809332B1 (en) | Compositions for multi-step delivery of hot-spots radiation to cancer cells | |
WO2022179483A1 (zh) | Siglec-15结合蛋白的制备及其用途 | |
JP2001522601A (ja) | 細菌タンパク質を用いる核ターゲティング | |
JPH06507900A (ja) | 腫瘍性細胞増殖の治療用のサイトカイン受容体を標的とした分子 | |
JPH0779795A (ja) | ヒトモノクローナル抗体産生株の製造法 | |
Doll | Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050620 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050620 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407 |